PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'NYU Langone Health, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, United States. Electronic address: Bhavana.Pothuri@nyulangone.org.\', \'Duke Cancer Institute, Duke University Health System, Durham, NC, United States.\', \'Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, United States.\', \'California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco, CA, United States.\', \'University of Alabama at Birmingham, Birmingham, AL, United States.\', \'Penn State Hershey Medical Center, Hershey, PA, United States.\', \'Dana-Farber Cancer Institute, Boston, MA, United States.\', \'University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, United States.\', \'University of Texas, MD Anderson Cancer Center, Houston, TX, United States.\', \'Levine Cancer Center, Atrium Health, Charlotte, NC, United States.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0090-8258(20)30994-X10.1016/j.ygyno.2020.04.694
?:hasPublicationType
?:journal
  • Gynecologic oncology
is ?:pmid of
?:pmid
?:pmid
  • 32386911
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.339
?:rankingScore_hIndex
  • 141
?:title
  • Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32386911>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32386911>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all